Featured Research

from universities, journals, and other organizations

Area Of Research Outlined For Promising New Cancer Drugs

Date:
May 13, 1998
Source:
University Of Notre Dame
Summary:
The effects of angiostatin and endostatin on mechanisms regulating angiongenesis in other processes besides tumor growth is one area of research that requires additional study, according to noted University of Notre Dame blood chemist Francis J. Castellino.

The effects of angiostatin and endostatin on mechanisms regulating angiongenesis in other processes besides tumor growth is one area of research that requires additional study, according to noted University of Notre Dame blood chemist Francis J. Castellino.

Related Articles


Basic research conducted in Castellino's laboratory contributed to the identification of angiostatin, one of the promising new cancer drugs being heralded nationally this week. Angiostatin and endostatin are being given top priority by the National Cancer Institute and will be rushed to clinical trial in humans.

Castellino is very excited about the drugs' possibilities but cautions that more studies involving the basic science of these drugs are needed. Research now under way in Castellino's laboratories will attempt to address some of these issues.

Castellino, whose laboratory is without question one of the top handful studying blood clotting mechanisms, is Kleiderer-Pezold professor of biochemistry, dean of Notre Dame's College of Science, and director of the Center for Transgene Research and the Walther Cancer Center, which are also at the University. It was his antibody to plasminogen, a precurser of the clot-dissolving enzyme plasmin -- as well as a number of basic studies on plasminogen fragments -- that helped confirm angiostatin is a fragment of this protein. (Endostatin is derived from a different, unrelated protein, collagen XVIII.)

Angiostatin and endostatin were discovered in the laboratory of Dr. Judah Folkman, a cancer researcher at Children's Hospital in Boston. The drugs function by cutting off the blood supply to tumors, making even extremely large tumors disappear. In mice, the drugs appear to stop malignant tumor growth and spreading, but they have not yet been tested in humans, and the medical community remains cautious.

Both angiostatin and endostatin evidently interfere with the tumors' ability to synthesize new capillaries from pre-existing blood vessels, a process called angiogenesis. Essentially, the tumors were starved when the drugs were administered to cancer-bearing mice.

Normally, only limited angiogenesis takes place in organisms after fetal development. Apart from pathological situations, such as cancer, angiogenesis is needed for events such as embryogenesis, wound repair, and successful skin grafts. "It's important to remember that cancer patients are sick," he explains. "There are other pathologies besides tumors. Many such patients experience difficulties with clotting, bleeding, and vascular damage, for example, and may require some level of neovascularization.

"We have to be careful not to elevate expectations to unreasonable levels prior to the results of clinical trials. However, on the other side, the potential beauty of these drugs is that they may only be required for short-term treatment, and that many of these other issues will be manageable."

A collaborative project between scientists at the Cleveland Clinic, the Notre Dame Center for Transgene Research, and the Walther Cancer Center will study genetically manipulated mice with deletions of angiostatin's parent protein, plasminogen. Results from this in vivo research are expected to yield greater understanding of the angiostatin-plasminogen relationship in cancer, Castellino says.

For more information, contact Frances J. Castellino, Kleiderer-Pezold professor of biochemistry and dean of the College of Science, at (219) 631-6456 or Elliot D. Rosen, research associate professor and associate director of the Transgene Research Center, at (219) 631-9365. Castellino's research is funded by the National Institutes of Health and the American Heart Association. He also has received funding from EntreMed, the Rockland, Md., biotech company that was formed to make and market angiostatin and endostatin, and from the Walther Institute of Indianapolis.


Story Source:

The above story is based on materials provided by University Of Notre Dame. Note: Materials may be edited for content and length.


Cite This Page:

University Of Notre Dame. "Area Of Research Outlined For Promising New Cancer Drugs." ScienceDaily. ScienceDaily, 13 May 1998. <www.sciencedaily.com/releases/1998/05/980513080147.htm>.
University Of Notre Dame. (1998, May 13). Area Of Research Outlined For Promising New Cancer Drugs. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/1998/05/980513080147.htm
University Of Notre Dame. "Area Of Research Outlined For Promising New Cancer Drugs." ScienceDaily. www.sciencedaily.com/releases/1998/05/980513080147.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins